Generalized Anxiety Disorder (GAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Generalized Anxiety Disorder (GAD) Market Outlook

Thelansis’s “Generalized Anxiety Disorder (GAD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Anxiety Disorder (GAD)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Generalized Anxiety Disorder (GAD) Overview

Generalized anxiety disorder (GAD) is a mental health condition characterized by persistent feelings of fear, worry, and being overwhelmed. It involves excessive and unrealistic concerns about daily matters, possibly stemming from various factors such as stress, underlying medical conditions like diabetes, co-existing conditions like depression, genetic predisposition (with about a 25% likelihood among first-degree relatives), and environmental influences like childhood trauma or substance abuse. While the exact cause remains unclear, research suggests the involvement of neurotransmitter systems like noradrenaline and serotonin in the body’s stress response, with low serotonin activity and heightened noradrenergic activity potentially contributing to its development. Normal anxiety can manifest in children, typically starting with stranger anxiety around seven to nine months of age. Diagnosis of GAD may involve thyroid function tests, blood glucose monitoring, echocardiography, and toxicology screening. Treatment options primarily revolve around cognitive behavioral therapy and medications, with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) being preferred due to their ability to modulate these neurotransmitter systems. Response rates to these medications typically range from 30% to 50%. XANAX (1981) is the approved product for the treatment of Generalized anxiety disorder (GAD).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Generalized Anxiety Disorder (GAD)  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034